Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amgen (AMGN)

Amgen Q4 revenue up 9% to $9.9 billion; full-year 2025 GAAP EPS up 88% to $14.23

Mixed Impact 4 of 5 earnings Written later

Amgen reported fourth-quarter and full-year 2025 results, with total revenue up 9% to $9.9 billion in the quarter and up 10% to $36.8 billion for the year. Full-year non-GAAP EPS rose 10% to $21.84, while fourth-quarter non-GAAP EPS was roughly flat at $5.29, and the company guided 2026 total revenue to $37.0 billion to $38.4 billion. Shareholders also face the FDA's January 16, 2026 request that TAVNEOS be voluntarily withdrawn from the U.S. market, which the filing does not quantify.

Key points

  • Full-year total revenue rose 10% to $36.8 billion; fourth-quarter total revenue rose 9% to $9.9 billion.
  • Full-year GAAP EPS rose 88% to $14.23 and non-GAAP EPS rose 10% to $21.84; fourth-quarter non-GAAP EPS was $5.29 versus $5.31.
  • 2026 guidance: total revenue of $37.0 billion to $38.4 billion and non-GAAP EPS of $21.60 to $23.00.
  • On January 16, 2026, the FDA requested that ChemoCentryx voluntarily withdraw TAVNEOS from the U.S. market.

The filing

CompanyAmgen (AMGN)
Form8-K, current report
Filed with the SECFeb 3, 2026, 4:03 PM ET
Accession number0000318154-26-000003

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.